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Coexistent type 2 diabetes and obesity—often termed
“diabesity”—is an emerging epidemic that poses a challenge to
the treatment of both conditions.1More than 90% of the world’s
285 million people with diabetes have type 2 diabetes, and this
number is projected to grow to 438 million by 2030.2 In North
America about 90% of people with type 2 diabetes are obese
(body mass index >30 (weight (kg)/height (m)2)), overweight
(body mass index 25-29.9), or have a medical history of being
so, and those who are not overweight may carry an excess of
hidden visceral fat.3 A large cohort study estimated that a body
mass index of 30-34.9 (compared with 22) for 16 years increased
the risk of type 2 diabetes more than 20-fold in women, and a
large cross sectional study of North American men aged 25-54
estimated that a body mass index of 30-34.9 increased the risk
more than 10-fold.w1 w2
In principle, lifestyle measures such as diet and exercise could
prevent the onset and greatly help the treatment of type 2
diabetes and obesity. In practice this is seldom borne out. Few
of the current treatments for type 2 diabetes facilitate weight
loss, and some cause weight gain (table 1). Because excess
adiposity presents a considerable hurdle to the control of
hyperglycaemia, therapeutic approaches that simultaneously
deal with glycaemic control and weight management are
particularly attractive for the treatment of type 2 diabetes.
This article examines existing and new treatments that have the
potential to treat coexistent diabetes and obesity and explores
the evidence from recent randomised trials and early
experimental research.
How do diabetes and obesity interact?
Metabolic homoeostasis is crucially dependent on insulin (fig
1). The hyperglycaemia and associated metabolic disturbances
of type 2 diabetes are usually caused by impaired insulin action
(insulin resistance) and defective insulin secretion, plus other
endocrine abnormalities such as hyperglucagonaemia. These
derangements and their attendant morbidity are greatly increased
by coexistent obesity, and the risk of death is more than
doubled.3 4 Each condition arises through a mix of genetic
susceptibilities and environmental factors. Genetic
polymorphisms and variations in the expression of genes that
affect feeding behaviour and metabolism can result in increased
storage of nutrients. This in turn accentuates further genetic
vulnerabilities that disturb insulin secretion and interfere with
the action of insulin on tissues.5 Environmental factors such as
inappropriate quality and excess quantity of nutrients,
insufficient physical activity, low grade inflammation, and
oxidative stress combine with genetic factors to increase
adiposity and insulin resistance. For example, excess fatty acids
and cytokines from adipose tissue (adipokines) such as tumour
necrosis factor α, interleukin 6, retinol binding protein 4, and
resistin impair the action of insulin.4 Insulin resistance initially
leads to a compensatory hyperinsulinaemia, but as insulin output
fails to meet the demands for insulin created by insulin
resistance, a state of impaired glucose tolerance emerges.
Progression to type 2 diabetes will depend on the extent of islet
β cell dysfunction and failure, and unintentional weight loss
signals severe insulin deficiency.
How do available treatments for diabetes
influence diabesity?
Interventions to promote weight loss
In obese patients with established diabetes long term randomised
controlled trials have shown that an intentional and sustained
reduction in body weight by 5-10% can lower glycated
haemoglobin (HbA1c) by 0.5-1% (5-11mmol/mol) and increase
life expectancy by 2-4 years.3w3 However, when people with
diabetes start to lose weight their insulin sensitivity improves,
favouring the anabolic efficacy of insulin and making it harder
to lose more weight. Reduced hyperglycaemia prevents the loss
of calories through glucosuria.
The intestinal lipase inhibitor orlistat is the only antiobesity
drug now available for prescription in the United Kingdom.
Randomised trials have shown that orlistat reduces weight by
2-3 kg more than placebo in obese patients with diabetes, with
a concomitant reduction in HbA1c of 0.3-0.5% (3-5 mmol/mol).
6
Orlistat may also help patients adhere to dietary restrictions but
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Summary points
The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition
Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes
Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors,
and α glucosidase inhibitors are typically weight neutral
The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients
New treatments should ideally reduce hyperglycaemia and excess adiposity
Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption
and cellular glucocorticoid activation, and activators of cellular energy production
Sources and selection criteria
This article is largely based on a search, focused on the treatment of hyperglycaemia, of original articles published between
2005 and 2010 usingMedline, PubMed, Cochrane Library, andGoogle Scholar. Themain search terms were hyperglycaemia,
diabetes, diabesity, and obesity together with therapy, treatment, or control. Papers identified were English language with
full text available. Reference lists of recent reviews were searched, along with abstracts of the American Diabetes Association
and European Association for the Study of Diabetes 2007-10.
is not a recognised part of current treatment algorithms for type
2 diabetes.
Observational studies have found that bariatric surgery is
effective in patients with obesity and diabetes, reinstating near
normal glycaemia in 50-80% of patients for several years.7 In
England bariatric surgery increased more than 10-fold from 238
procedures in 2000 to 2543 in 2007 but is not suitable,
acceptable, or affordable for all.w4
Glucose lowering agents
Table 1 lists the currently prescribed glucose lowering agents
and fig 2 shows their main sites of action. Because insulin
promotes adipogenesis and weight gain, insulin itself and agents
that increase its secretion or actions can restrict their own
efficacy in obese people unless they also counter weight gain.4 8
Randomised controlled trials have shown that metformin is
“weight neutral”—it improves the action of insulin but exerts
metabolic effects that increase energy dissipation and offset
weight gain. Glucagon-like peptide 1 (GLP-1) receptor agonists
potentiate insulin secretion and exert a satiety effect that reduced
weight by 2-4 kg in most patients during randomised controlled
trials. Inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4)
also potentiate insulin secretion, largely through reduced
degradation of incretins such as GLP-1, and are also weight
neutral, possibly because of a mild satiety effect. Inhibitors of
α glucosidase, which slow down carbohydrate digestion, can
reduce the amount of prandial insulin secretion and help control
weight in some patients. Other oral antidiabetic drugs that
increase insulin secretion (sulphonylureas and meglitinides) or
improve insulin action (thiazolidinediones) tend to cause weight
gain.8
Other glucose lowering drugs
Several other drugs that are not approved as glucose lowering
agents in Europe are weight neutral or facilitate a small reduction
in body weight. These include the amylin analogue pramlintide,
a low dose quick release formulation of the dopamine agonist
bromocriptine, and the bile sequestrant colesevelam.
Intensive glycaemic control in patients with
type 2 diabetes
Although recent high profile prospective trials of intensive
glycaemic control found that late intensification of treatment
did not prevent mortality from cardiovascular disease, it did
reduce microvascular disease.w5 These findings should not
detract from observational evidence that early intensive
glycaemic control reduces microvascular and macrovascular
complications and that it may take a decade or more for
macrovascular benefits to be seen.w6 This suggests the existence
of “glycaemic memory,” and that effective glycaemic control
is needed from diagnosis to reduce complications decades later.
Which agents may allow effective
treatment of diabetes and obesity in
future?
New drugs have the potential to reduce both hyperglycaemia
and excess adiposity. GLP-1 receptor agonists (twice daily
injected exenatide and once daily injected liraglutide) fit this
profile.9w7 Looking to the future, a once weekly subcutaneously
injected formulation of exenatide—exenatide QW—is advanced
in development.
Exenatide QW
This depot formulation encapsulates exenatide in biodegradable
microspheres comprising polymers of lactic acid and glycolic
acid, and it has been tested in a series of open label randomised
six month studies. In a study of 258 overweight and obese
patients with type 2 diabetes already receiving metformin or a
sulphonylurea (or both) with a baseline HbA1c of 8.5% (70
mmol/mol), HbA1c was lowered by 1.9% (21 mmol/mol) in
patients prescribed 2 mg exenatide QW compared with 1.5%
(16 mmol/mol) in patients prescribed standard exenatide 10 µg
twice daily.10 This reduction was maintained to one year, weight
loss averaged more than 4 kg, and the side effect of nausea was
less common with QW than with standard exenatide. In 491
overweight and obese patients with diabetes and a baseline
HbA1c of 8.5% (70 mmol/mol) already taking metformin, 2 mg
exenatide QW reduced HbA1c by 1.7% (18 mmol/mol) and
reduced body weight by 2.8 kg at six months, compared with
1.0% (11 mmol/mol) and 0.9 kg in those taking 100 mg
sitagliptin once daily and 1.4% (15 mmol/mol) and 3.4 kg in
those taking 45 mg pioglitazone once daily.w8 Another study
compared 2mg exenatide QW for 26weeks with insulin glargine
(mean daily dose 31 U/day at end point) in 456 overweight and
obese patients with diabetes taking metformin with or without
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sulphonylurea who had a baseline HbA1c of 8.3% (68
mmol/mol).w9 Exenatide QW reduced HbA1c by 1.5% (16
mmol/mol) and reduced weight by 2.6 kg compared with 1.2%
(13 mmol/mol) and an increase of 1.4 kg for glargine. A head
to head study of 912 patients recently found that 2 mg exenatide
QW for 26 weeks reduced HbA1c by 1.3% (14 mmol/mol)
compared with a reduction of 1.5% (16 mmol/mol) with 1.8 mg
daily liraglutide.11
Possible drawbacks to using longer acting GLP-1 receptor
agonists include potential injection site reactions, acute
reactions, “resistance,” and the development of antibodies. The
prevalence of pancreatitis in patients using exenatide seems to
be no higher than for the diabetic population in general, although
this remains open to debate. Because exenatide is degraded and
eliminated by the kidneys, patients must have adequate renal
function.w10
Other GLP-1 based treatments
Other once weekly GLP-1 receptor agonists under study include
CJC-1134, a variant of exenatide linked to albumin, and
taspoglutide.12w11 Albiglutide, is a dimeric GLP-1 analogue
(Ala8Gly) that is fused to human albumin and acts for as long
as two weeks.13 Lixisenatide, a variant of exenatide, is shorter
acting but suited to once daily injection in combination with
insulin glargine.14 Limited phase I and phase II data on these
drugs suggest that they have similar efficacy to other members
of the class. A long chain polymer of GLP-1 that is slowly
degraded in the circulation by endopeptidases is at an early stage
of testing.15 Delivery of GLP-1 analogues by buccal, oral, and
nasal routes and dermal patches, rather than injections, is being
investigated.
Oxyntomodulin is an extended glucagon-like peptide produced
by ileal L-cells along with GLP-1.16 Oxyntomodulin has
glucagon receptor and GLP-1 receptor agonist properties, and
its analogues are being investigated for the treatment of obesity.
They combine the satiety inducing and pancreatic effects of
GLP-1 with the lipolytic effects of glucagon—the glucose
lowering effect of the GLP-1 moiety overcomes the
hyperglycaemic effect of the glucagon.w12 Although they may
not be ideally suited for diabetes and obesity, other hybrids such
as a GLP-1 receptor agonist with a glucagon antagonist have
been produced; the glucagon antagonist enables the molecule
to occupy the glucagon receptor without triggering post-receptor
signalling.17
Small (non-peptide) GLP-1 receptor agonists and glucagon
receptor antagonists suitable for oral administration have
recently shown proof of principle in animal studies.18 19w13 w14
Neutralisation of glucagon can promptly reduce hyperglycaemia,
but this approach may reduce the defence against an episode of
hypoglycaemia, because glucagon is a key blood glucose raising
hormone. Also, glucagon antagonists may cause a compensatory
rise in glucagon and a rebound increase in the effect of glucagon
if the antagonism is lifted.
Preclinical and phase I studies have identified small molecule
agonists of someG protein coupled receptors such as GPR-119,
which act directly on the intestine and pancreas to stimulate
secretion of incretins and insulin.20 They have also reduced food
intake and curbed weight gain in rodents.
DPP-4 inhibitors
The advantages of current DPP-4 inhibitors (sitagliptin,
vildagliptin, and saxagliptin) in lowering blood glucose without
weight gain have been reviewed elsewhere.21 Other DPP-4
inhibitors, notably linogliptin and alogliptin, are advanced in
development; they have similar efficacy but different
pharmacokinetic properties that may make them suitable for
use in patients with diabetes and obesity, particularly those with
comorbidities or taking other drugs.w15 w16
Agents that exploit lessons learnt from
bariatric surgery
As well as reducing weight, bariatric surgery rapidly improves
and maintains glycaemic control. Although this approach is not
practical for all patients, “metabolic surgery” is now an accepted
treatment for obese patients with diabetes.7w17 The finding that
glycaemic control is promptly reinstated in most patients with
diabetes when less food passes through the stomach, duodenum,
and proximal jejunum—independently of the amount of weight
lost—has focused attention on research into gastrointestinal
factors as a potential source of new drugs for treating diabetes.22
Several gastrointestinal peptides could provide a basis for new
treatments in patients with obesity and diabetes (table 2).23
Reduced secretion of ghrelin, an orexigenic hormone from the
stomach, has been seen after bariatric surgery, but this has not
been a consistent finding, and its effects on islet function are
variable, casting doubt on the therapeutic value of a ghrelin
antagonist.w18 Peptide YY (PYY), another hormone produced
by the ileal L-cells, is reduced in obese people and those with
type 2 diabetes and increased after gastric bypass surgery. As
a Y2 receptor agonist, this hormone has an anorectic effect that
might be useful in obesity, but its effect on glucoregulation
remains to be clarified.24
Although glucose dependent insulinotrophic polypeptide (GIP)
contributes to the incretin effect, GIP receptor knockout mice
and obese-diabetic animals treated with GIP receptor antagonists
have shown improved glucose control with reduced weight gain,
suggesting that GIP antagonism might be a useful approach.25
SGLT2 inhibition: reduced renal glucose
reabsorption
Hyperglycaemia could be reduced and calories lost by increasing
the elimination of glucose in the urine. Although this does not
tackle the underlying endocrinopathy it could help to control
symptoms of glucotoxicity and reduce the morbidity associated
with hyperglycaemia. Normally most of the glucose in the
glomerular filtrate is reabsorbed by the sodium-glucose
cotransporter 2 (SGLT2) in the initial part of the proximal
tubule. Remaining glucose is reabsorbed by SGLT1 further
along the proximal tubule. Inhibition of these transporters can
reduce glucose reabsorption.26 However, SGLT1 is also
responsible for glucose absorption by the intestine, and its
inhibition may lead to glucose malabsorption. Specific or
predominant inhibition of SGLT2 is therefore needed.
Dapagliflozin is the first selective SGLT2 inhibitor to be
extensively investigated. In randomised double blind controlled
trials over six months to one year it reduced HbA1c by 0.5-1%
(5-11mmol/mol) and lowered bodyweight by 2-3 kg compared
with placebo, either as monotherapy or add-on to other oral
antidiabetic agents or insulin in overweight and obese patients
with diabetes.26w19 This effect is associated with glucosuria of
50-80 g/day (compared with a normal filtered glucose load of
more than 200 g/day). The risk of hypoglycaemia is low because
a fall in blood glucose below normal allows SGLT1 to reabsorb
almost all of the filtered glucose. Moreover, the mechanism is
independent of insulin and not reduced by the progressive
deterioration of insulin secretion or action as diabetes gets worse.
Adverse effects include infections in the urinary tract and
urinogenital region. A modest persistent osmotic diuresis was
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evident, which may have contributed to the consistent small
reduction in blood pressure. Other SGLT2 inhibitors in early
stages of clinical development show similar glucose lowering
and weight lowering properties.26
Glucocorticoid antagonists
Because raised concentrations of glucocorticoids promote truncal
obesity, insulin resistance, and hyperglycaemia, strategies have
been developed to reduce the action of glucocorticoids by
targeting hepatic glucose production and adipogenesis. One
mechanism for delivering glucocorticoid receptor antagonists
to the liver has been conjugation with a bile salt, so that the
antagonist is recycled in the enterohepatic circulation.w20 This
has reduced hepatic glucose production and improved glycaemic
control in obese-diabetic animal models.
Another approach has exploited the cellular conversion of less
active cortisone to more active cortisol by the enzyme 11β
hydroxysteroid dehydrogenase 1.w21 In a 12 week randomised
double blind placebo controlled trial of 302 overweight and
obese patients with type 2 diabetes inadequately controlled with
metformin, addition of INCB-13739 (up to 200 mg/day), a
selective inhibitor of 11β hydroxysteroid dehydrogenase 1,
improved insulin sensitivity, lowered body weight by 1-2 kg,
improved the plasma lipid profile, and reduced HbA1c by 0.6%
(6 mmol/mol).27
Enhancers of insulin activity
Several new mechanisms to improve the action of insulin have
shown beneficial effects on glycaemic control in obese and
diabetic rodents without reducing excess adiposity, but they
have yet to be assessed in human patients.28
Considerable interest has focused on agents that activate AMP
activated protein kinase, an energy regulating enzyme that is
activated by metformin, thiazolidinediones, and adiponectin.29
Stimulation of this enzyme reduces the expression of rate
limiting enzymes for gluconeogenesis in the liver, thereby
reducing hepatic glucose production. AMP activated protein
kinase also increases fatty acid oxidation in liver and muscle
and promotesmitochondrial biogenesis. Various novel activators
of this protein kinase have shown proof of principle by
improving glycaemic control in insulin resistant obese and
diabetic animals with a variable effect on weight control.30w22
Hypothalamic targets
Centres within the hypothalamus continually sense neural flux
rates for glucose and fatty acid metabolism and initiate vagally
mediated adjustments to hepatic glycogenolysis and
gluconeogenesis.31 The extent to which hypothalamic control
of glucose homoeostasis inter-relates with the hypothalamic
control of appetite and satiety is not clear.
Antidiabetic adipokines
Glucoregulatory andweight modulating hormones from adipose
tissue may prove useful in the treatment of diabetes and
obesity.32 The adipocyte hormone leptin, in addition to its
centrally mediated satiety and thermogenic effects, can suppress
the secretion of glucagon, alter the production of insulin-like
growth factor binding protein-2, and exert direct effects on
cellular nutrient metabolism.w23 Each of these effects could help
lower blood glucose, so leptin has recently been considered as
an adjunctive treatment for type 1 and type 2 diabetes, either
alone or combined with other antiobesity agents.33 The
development of antibodies and resistance to persistently high
concentrations of leptin interfere with such treatment, however,
so leptin analogues and non-peptide receptor agonists are being
investigated.
Another adipocyte hormone, adiponectin, activates AMP
activated protein kinase, improves insulin sensitivity, lowers
blood glucose concentrations, improves weight control and
vascular reactivity, and reduces inflammation in obese and
diabetic animals.32
A further adipokine, zinc-α2-glycoprotein has recently been
shown to induce weight loss and improve glycaemic control in
obese diabetic rodents.34
Conclusion
The burgeoning epidemic of coexistent diabetes and obesity
and the lack of available drugs, despite substantial research, is
worrying.
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Tips for non-specialists
Every consultation is an opportunity to reinforce healthy lifestyle advice
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exercise in any way and at any time that they can
Encourage weight loss by overweight and obese family members to support the patient
Be cautious in the treatment of comorbidities with agents that can cause weight gain (for example, steroids, some
antipsychotics)
If a drug does not benefit glycaemic control or weight loss within three months, consider discontinuation
Trying to lose weight can improve glycaemic control even without weight loss
Future research
How to introduce practical measures to reinstate a culture of healthy living that includes physical activity
Identifying new treatments to prevent pancreatic β cell failure and to dissipate energy without reducing lean body mass
Predicting who will be most responsive to a particular treatment
Determining early markers of susceptibility for increased appetite, metabolic efficiency, and sedentary choices
Additional educational resources
Resources for healthcare professionals
Each of the following sites provides a range of well structured and authoritative educational resources for all healthcare
professionals
European Association for the Study of Diabetes (www.easd.org/)
International Diabetes Federation (www.idf.org/)
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Tables
Table 1| Current treatments for type 2 diabetes
Cautions and contraindications*Bodyweight
Reduction in
fasting plasma
glucose (mmol/L)
Reduction in HbA1C
(%; mmol/mol)Main mechanisms of actionAgent
Agents administered orally
Gastrointestinal side effects; lactic
acidosis (rare); contraindicated if renal
impairment or any hypoxaemic condition
↓/–1-4~1-2 (~11-22)Reduces insulin resistance† and
hepatic glucose output; increases
peripheral glucose utilisation and
glucose turnover between intestine and
liver
Metformin
Risk of severe hypoglycaemia; use
restricted by severe liver disease, renal
disease, or porphyria
↑2-4~1-2 (~11-22)Directly increase insulin secretion‡;
bind to SUR1 receptor on β cells
Sulphonylureas
(glibenclamide,
gliclazide, glimepiride,
glipizide, tolbutamide)
Less of a risk of hypoglycaemia (than
with sulphonylureas); use restricted by
liver disease or severe renal disease
↑/–1-3~0.5-1.5 (~5-16)Directly increase insulin secretion‡§;
bind to benzamido site on SUR1
receptor; rapid onset, short duration of
action
Meglitinides (repaglinide,
nateglinide)
Small risk of hypoglycaemia (seldom
severe), mostly when used with other
glucose lowering agents; use restricted
by substantial renal disease or liver
disease
–0.6-1.2~0.6-1.5 (~6-16)Increase insulin secretion‡; prevent
degradation of incretin hormones by
DPP-4, which allows incretins longer
potentiation of nutrient induced
(prandial) insulin secretion
Gliptins (DPP-4
inhibitors: sitagliptin,
vildagliptin, saxagliptin)
Caution concerning heart failure,
oedema, fluid retention, anaemia,
fractures precluded by cardiac disease,
severe liver disease, or renal disease
↑2-3~0.6-2.0 (~6-22)Increase insulin action† and
adipogenesis; stimulate PPAR-γ; alter
glucose-fatty acid cycle
Thiazolidinediones, such
as pioglitazone
Gastrointestinal discomfort; avoid if
intestinal diseases, severe kidney, or liver
disease
–~0.5~0.5-1.0 (~6-11)Slows carbohydrate digestion¶α glucosidase inhibitor
(such as acarbose)
Agents administered by subcutaneous injection
Nausea; risk of hypoglycaemia when
used with other glucose lowering agents;
avoid in severe renal disease or
gastroparesis; stop if pancreatitis is
suspected
↓0.7-2.5~0.5-2.0 (~6-22)Increase insulin secretion‡ and
decrease glucagon secretion; resistant
to degradation by DPP4; potentiate
nutrient induced (prandial) insulin
secretion
GLP-1 receptor agonists
(exenatide, liraglutide)
Risk of severe hypoglycaemia;
substantial lifestyle adjustments needed;
glucose monitoring
↑Adjust dose and
regimen as
needed
Adjust dose and
regimen as needed
Decrease lipolysis and hepatic glucose
output; increase peripheral glucose
uptake, storage, and utilisation
Insulins
*Most agents can rarely cause hypersensitivity reactions.
†Requires presence of circulating insulin.
‡Requires presence of a functional β cell mass.
§Take with meals to reduce the risk and severity of hypoglycaemia.
¶Take with meals rich in complex carbohydrate.
DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; PPAR-γ, peroxisome proliferator activated receptor γ; SUR, sulphonylurea receptor; ↑, increase;
↓, decrease; –, no change.
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Table 2| Actions of gastrointestinal hormones that can affect appetite, satiety, and glucoregulation*
Effects of hormonePlasma concentration of hormone
Hormone
Glucagon
secretionInsulin secretionAppetite/meal size
Bariatric surgery
In type 2 diabetes RestrictionBypass
↑↑↓??↑Cholecystokinin
–/↑↑–??–Gastrin
?↑/↓↑↑?–/↓?↓Ghrelin
–/↑↑–––/ –/↑GIP
↓↑↓–↑–/↓GLP-1
–/↓↓↓–?↑↓Peptide YY
↑↑–/↓–??–/↑Secretin
↓↓↓???–/↓Somatostatin
*GIP, glucose dependent insulinotrophic polypeptide (gastric inhibitory polypeptide); GLP-1, glucagon-like peptide 1; –, no change; ?, not clear (inconsistent reports
or the reliability of some of the studies is questionable);  , increase;  , decrease.
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Figures
Fig 1 Pathogenesis of type 2 diabetes with obesity. Genetic factors and environmental impositions confer susceptibility to
weight gain, insulin resistance, and pancreatic β cell dysfunction. Excess adiposity promotes insulin resistance, which is
initially compensated for by increased insulin concentrations. When the insulin concentrations are unable to overcome the
insulin resistance then hyperglycaemia develops. Continued deterioration of β cell function causes further impairment of
glucose homoeostasis into type 2 diabetes
Fig 2Main sites of action of agents currently used to treat hyperglycaemia in type 2 diabetes. *Bromocriptine, colesevelam,
and pramlintide are not licensed for the treatment of hyperglycaemia in Europe. DPP-4, dipeptidyl peptidase 4; GLP-1,
glucagon-like peptide 1
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